Effects of Fluoxetine Treatment on Striatal Dopamine Transporter Binding and Cerebrospinal Fluid Insulin-Like Growth Factor-1 in Children with Autism
Abstract
A positive effect of fluoxetine has been shown in some children with autism. The present study was undertaken to correlate striatal dopamine transporter (DAT) binding and cerebrospinal fluid insulin-like growth factor-1 (CSF-IGF-1) with clinical response in autistic children (n=13, age 5-16 years) after a 6-month fluoxetine treatment. Good clinical responders (n=6) had a decrease (p=0.031) in DAT binding as assessed using single-photon emission computed tomography with [123I]-nor-β-CIT, whereas poor responders had a trend to an increase. An increase in CSF-IGF-1 (p=0.003) was detected after the treatment period, but no correlation between the clinical response and CSF-IGF-1 was found. In conclusion, fluoxetine decreases DAT binding indicating alleviation of the hyperdopaminergic state and increases CSF-IGF-1 concentration, which may also have a neuroprotective effect against dopamine-induced neurotoxicity in autistic children.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a small pilot study of 13 children with ASDs who received a 6-month course of fluoxetine, good clinical responders had a significant decrease in striatal DAT binding.
“A small pilot study of 13 children with ASDs who received a 6-month course of fluoxetine treatment showed that good clinical responders had a significant decrease in striatal DAT binding [589]”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [589]
Cited by
Sorted by citations
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works
Dysregulation of the IGF‐I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders
Chen, J., Alberts, I., & Li, X. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.03.006 · Cited by 151 · see citing works
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108 · see citing works
- Authors
- Makkonen, I., Kokki, H., Kuikka, J., Turpeinen, U., & Riikonen, R.
- Affiliations
- University of Eastern Finland (FI)
- Department of Anesthesiology and Intensive Care
- Imaging Center
- HUSLAB, Laboratory of Women’s Clinic
- Department of Pediatrics, Unit of Child Neurology
- Corresponding author
- Riikonen, R.
- Venue
- Neuropediatrics
- Publisher
- Georg Thieme Verlag KG
- Published
- 2011-10
- Volume
- 42
- Issue
- 05
- Pages
- 207-209
- ISSN
- 0174-304X (ISSN-L)
- 1439-1899
- OpenAlex
- W2025012341
- Cited by
- 37
- References
- 0
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 3 · 2012: 3
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuropediatrics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Suomen Kulttuurirahasto
- Northern Savo Hospital District
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- fluoxetine, autism spectrum disorder, striatal dopamine transporter, dopamine transporter binding, hyperdopaminergic state, treatment response, neuroprotection, dopamine neurotoxicity, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child, Preschool, Corpus Striatum, Female, Fluoxetine, Humans, Insulin-Like Growth Factor I, Male, Tomography, Emission-Computed, Single-Photon, Selective Serotonin Reuptake Inhibitors, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
